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Background: Participation in cancer clinical trials has been shown to increase overall survival with
minimal increase in cost, but enrollment in adult cancer clinical trials remains low. One factor limiting
enrollment is lack of insurance coverage, but this barrier should be reduced under the 2010 Patient
Protection and Affordable Care Act (ACA), which includes a provision requiring coverage for clinical trial
participation as of 2014.
Methods: To assess the number of Kansas adults aged 19e64, newly covered with health insurance for
participation in oncology clinical trials as a result of the ACA, a cross sectional design using extracted data
from the 2012 American Community Survey, Public Use Microdata Sample to estimate the number of
individuals covered by insurance and data from the 2014 Department of Health and Human Services
Health Insurance Marketplace enrollment to estimate those newly enrolled through ACA.
Results: In 2014, there was an estimated increase of 3% (54,397; 95% CI: 44,149e64,244) for a total of 72%
(1,171,041) of Kansans aged 19 to 64 with health insurance coverage for clinical trial participation.
Conclusion: Three main factors limit the effectiveness of the ACA provisions in expanding clinical trial
coverage: 1) ‘grandfathered’ self-funded employer plans not subject to state Employee Retirement In-
come Security Act (ERISA) regulations, 2) Medicaid coverage limits not addressed under the ACA, 3)
populations that remain uninsured. Kansas saw a negligible increase in insurance coverage as a result of
the ACA thus lack of insurance coverage is likely to remain a concern for cancer patients.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
An estimated 37 million individuals will be newly insured with
health insurance coverage due to the ACA over the next 10 years;
many of whom may have been without access to high-quality
cancer prevention, early detection and treatment services [1].
Cancer is the second leading cause of death in the United States and
in 2014, it was estimated that 1,665,540 new cancer cases would be
diagnosed and about 585,720 Americans would die from cancer [2].
The development of investigational compounds is crucial in the
quest for advancing treatment options and discovering the cure for
cancer. Participants in clinical trials have access to cutting edgencer Center, 4350 Shawnee
y), tgurley-calvez@kumc.edu
rickson), rjensen@kumc.edu
Inc. This is an open access article uapproaches to treatment and technology and trial participation has
been shown to be associated with a higher survival rate [3,4].
However, less than 5% of cancer patients participate in clinical trials
despite nearly one-third of Americans indicating a willingness to
participate if asked [5,6].
The reasons affecting low accrual are varied and complex, but
include cost-related hurdles, speciﬁcally lack of insurance coverage,
especially those with private insurance compared to government-
funded insurance [3,7,8]. Potential denial of coverage was re-
ported as the reason for declining participation for 8e20% and as
high as 85% of eligible patients [9,10].
Removing the insurance coverage barrier is addressed in section
2709 of the 2010 Patient Protection and Affordable Care Act (ACA)
as new policies are required to cover routine costs for participation
in all phases of qualiﬁed clinical trials as of January 1, 2014. This
study examines how effective the ACA provisions have been for
increasing the number of Kansans with insurance coverage for
cancer clinical trials.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1 Medicare is federal health insurance coverage for individuals 65 years and older
and for those younger than 65 deemed disabled. Medicaid is a government health
insurance program for low-income households operated by states with federal
matching funds. TriCare is a health insurance program for active duty military
members, reserve members, military retirees and their families. The VA is an in-
tegrated health insurance and health care system for Veterans.
2 Indian Health Service (IHS) access was included in the no insurance tabulation
as IHS is not an insurance provider.
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Third party payers of health care costs have been covering
routine care procedures for patients participating in clinical trials
for decades, but this coverage has been steadily declining despite
evidence suggesting the incremental costs of receiving treatment
through a clinical trial is not signiﬁcantly different than receiving
treatment outside of the trial [11e14]. Prior to the ACA, the federal
government and many states attempted to address the issue of
clinical trial coverage by enacting legislation or adopting coopera-
tive agreements with insurance companies to ensure coverage for
cancer patients' routine procedures while participating in a clinical
trial [15]. Several factors limited the comprehensive nature of these
efforts including inconsistent state legislation and regulations that
do not apply to self-insured plans often offered by large employers,
and varying Medicaid coverage rules set by each state. Research
suggests these laws had varying effects on overall clinical trial
accrual rates [9,16e18] Nearly one in ﬁve individuals aged 19e64
were not covered for trial participation based solely on not having
health insurance coverage in 2012 [19].
3. ACA addresses coverage for trial participation
As of January 1, 2014, the ACA requires insurance providers of-
fering new policies as qualiﬁed health plans, to cover routine pa-
tient costs deﬁned as “all items and services consistent with the
coverage provided in the plan (or coverage) that is typically covered
for a qualiﬁed individual who is not enrolled in a clinical trial,
including hospital visits, imaging, laboratory tests and medica-
tions” and excludes any procedures or tests speciﬁcally related to
the research project and data collection [20]. However, absence of
regulations to enforce this mandate and exemptions for grand-
fathered plans, group plans and health insurance coverage with
enrollees prior to March 23, 2010, may signiﬁcantly impact the
outcome of this mandate on clinical trial coverage [21e23].
Lack of health insurance coverage for clinical trial participation
does not necessarily preclude a patient from participating in the
trial, but likely means the patient must assume responsibility for all
cancer treatment-related care while on the trial and risk denial of
coverage for other health services if the insurance company de-
termines that the cost is related to trial participation. As individuals
consider trial participation, they weigh their perceived beneﬁts,
including broader societal beneﬁts from cancer research, with
monetary and non-monetary costs of participation [24]. Although
research suggests patients are more likely to decline being a
research participant due to preferring the standard therapy or not
wanting to be on a trial, ﬁnancial and insurance issues were
frequently cited as reasons for non-enrollment when patients
desired treatment through a clinical trial [8].
4. Methods
We used current population survey data from the 2012 Amer-
ican Community Survey, Public Use Microdata Sample (PUMS) and
adjusted insurance coverage using estimates from the literature
and ACA marketplace enrollment numbers to estimate post-ACA
cancer clinical trial coverage [25]. ACA health insurance market-
place data was obtained from the United States (US) Census Bureau
and the United States Department of Health and Human Services
(HHS) report dated May 1, 2014 [26]. PUMS includes individual and
household-level data for a one percent sample of the US population
and is meant to be nationally representative of the US civilian, non-
institutionalized population. PUMS data are gathered through
interview and mail questionnaires on an ongoing basis and made
public yearly. The HHS report derives its numbers from the ACAhealth insurance open enrollment period from October 1, 2013 to
March 31, 2014, and includes the special enrollment period activity
through April 19, 2014.
PUMS data are used to estimate the number of Kansans covered
by type of health insurance in 2012. Estimates are adjusted for
sampling and response bias using the available weights. The HHS
report is used to estimate post-ACA insurance status. Note that we
use 2012 insurance status as the baseline to isolate the effects of
ACA coverage. Speciﬁcally, we apply percent changes in the unin-
sured to calculate 2014 estimated coverage assuming that the un-
derlying distribution in insurance status remains steady. This
allows us to capture ACA-related changes separate from trends in
insurance coverage between 2012 and 2014. State laws and regu-
lations and results from the literature are used to estimate the
proportion of individuals with each insurance coverage type (i.e.
employer, government, uninsured) who are covered for clinical trial
participation. Individual and household-level data for Kansas
adults aged 19 to 64 was chosen because older Americans were
generally covered prior to the ACA through Medicare, which began
covering trial participation in 2000 with the enactment of the
clinical trial policy national coverage determination (NCD) by the
Centers for Medicare andMedicaid Services [27]. Children up to the
age of 19 were generally covered through Medicaid or the Chil-
dren's Health Insurance Program and were not expected to have
signiﬁcant changes in coverage rates due to the ACA.
The seven insurance types collected in PUMS were grouped into
three categories: commercial payer (employer or union sponsored,
purchased directly from insurance company); government payer
(Medicare, Medicaid, TriCare, Veterans Health Administration
(VA))1; and no coverage2. When an individual was covered bymore
than one insurance plan, they were assigned to the category with
the highest cancer trial coverage rates (e.g. Medicare ﬁrst, employer
coverage second, Medicaid third). Once these categories were
developed, the proportion of individuals with insurance coverage
for clinical trial participation was estimated.
Point estimates from national survey data and the literature
were used to calculate the approximation of the newly insured.
Ninety-ﬁve percent conﬁdence intervals are used to calculate lower
and upper bound estimates of the newly insured. The results are
based on a study of Kansas and provide a framework for identifying
the policy areas fundamental to determining the ACA's impact
nationally. In Kansas, it was estimated that 14,630 new cancer cases
would be diagnosed and 5460 Kansans would die from cancer in
2014 [2].
Using the PUMS data as a baseline, changes in coverage type
were estimated using: ACA enrollment through the Marketplaces;
changes in employer coverage; changes in government coverage;
and changes in uninsured rates. PUMS data estimation and conﬁ-
dence intervals were calculated using Stata version 12.0. Estimates
of coverage changes were developed using Microsoft Ofﬁce Excel.
5. Results
The 2012 population of Kansans aged 19e64 was 1,627,427 (95%
CI: 1,602,848e1,652,007). Insurance coverage by category for these
individuals is represented in Fig. 1. Pre-ACA, eighty-four percent of
Fig. 1. Health Insurance Coverage by provider pre-ACA, Adults aged 19e64.
Source: Authors' calculations of PUMS data
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Kansans (71%. 95% CI: 69.8%e72.2%) were covered by commercial
health insurance policies through an employer, union or as a direct
purchase from an insurance carrier. Government sponsored pol-
icies including Medicare, Medicaid or other government assistance,
TriCare, and the Veteran's Administration, covered nearly 13% of
Kansans. An estimated 16% of Kansans were uninsured.
According to a study by Klamerus et al., 13.6% of individuals
were denied coverage for participation in a clinical trial by their
commercial insurance carrier [28]. Based on these data, a 13.6%
denial rate was used to calculate the number of Kansans in the
commercial category without insurance coverage for clinical trial
participation pre- and post-ACA. Although not reported in the
Klamerus et al. article, the 95% conﬁdence interval estimates pro-
vided by the study authors (S.S. Bruinooge, personal communica-
tion, January 23, 2015) of 12.6%e14.6% were used to calculate lower
and upper bound estimates.
The government category assumes 100% coverage for clinical
trial participation for Medicare, (based on the 2000 NCD),3 as well
as TriCare4 and the VA5. Clinical trial participation is not covered by
Medicaid in Kansas, therefore those with Medicaid (43% of the
government category) were not counted as having coverage either
pre- or post-ACA. Uninsured individuals were coded as having no
insurance coverage for clinical trial participation. A summary of
pre-ACA clinical trial coverage is presented in Fig. 2. An estimated
total of 69% (1,116,644: 95% CI: 1,091,912e1,141,445) of Kansans had
insurance coverage for clinical trial participation pre-ACA. Of those
without clinical trial coverage, 51% (95% CI: 48.53%e54.76%) had no
insurance coverage, 18% (95% CI: 16.42%e18.69%) were covered by
Medicaid, and 31% (95% CI: 30.27%e31.33%) were covered by
commercial insurance plans. Therefore, to achieve universal
coverage, the ACAwould have needed to address trial participation
coverage for each of these three groups.
Kansas did not develop its own state-based marketplace and3 https://www.cms.gov/Medicare/Coverage/ClinicalTrialPolicies/downloads/
ﬁnalnationalcoverage.pdf.
4 http://www.tricare.mil/Plans/SpecialPrograms/CancerClinicalTrials.aspx.
5 http://www.cancer.gov/clinicaltrials/learningabout/payingfor/federal-
government-programs.therefore uses the federally facilitated marketplace. As of May 1,
2014, 52,966 Kansans aged 18 to 64 had enrolled through the
marketplace6. Although it is unclear from the reported government
statistics howmany individuals were newly insured and howmany
were previously insured through another source, researchers have
estimated that 35.9% (95% CI: 17.95%e53.85%) of marketplace
enrollees were newly insured [29]. Estimates of insurance transi-
tions post-ACA are presented in Fig. 3. As noted earlier, it is esti-
mated that 13.6% of commercial plans did not cover trial
participation in 2012 therefore individuals who switched from
employer sponsored insurance (ESI) to a marketplace plan would
be newly covered. This yields 4618 individuals whowere previously
employer insured without clinical trial participation coverage that
are now newly covered for clinical trial participation.
Another group potentially affected by ACA provisions includes
those uninsured pre-ACA. Based on Marketplace enrollment sta-
tistics, most of the uninsured pre-ACA remained uninsured post-
ACA, largely attributable to no Medicaid expansion in Kansas. As
noted earlier, Kansas Medicaid does not cover clinical trial partici-
pation and Kansas opted not to expand Medicaid coverage. Thus,
individuals who were previously uninsured but eligible for
Medicaid, and newly enrolled in Medicaid because of ACA pro-
visions, gained health insurance coverage not clinical trial coverage.
The largest gains in insurance among the uninsured came from
the employer category. It is estimated that 30,766 of the 35,609
individuals with new employer-provided insurance are newly
covered for cancer clinical trial participation, due to approximately
14% of commercial plans not covering trial participation7. Finally, it
is estimated that a total of 19,013 individuals transitioned from
uninsured in 2012 to a Marketplace plan in 2014. All of these in-
dividuals were newly covered for cancer clinical trial participation.
In total, 54,397 (95% CI: 44,149e64,244) Kansans, or about 3% of6 Statistics for federally run marketplaces include 18-year olds in their reporting.
7 We use national estimates from Carman and Eibner (2014) to assess the share
in the reduction of the uninsured attributable to employer provided insurance.
Speciﬁcally, we calculate the percent with new employer insurance by dividing the
number newly insured in ESI (7.2 million) by the sum of those newly insured
(EST + Medicaid + Marketplace ¼ 7.2 + 3.6 + 1.4 ¼ 12.2 million) to arrive at 59
percent of newly insured from these categories in employer plans.
• Remained ESI: 1,121,032
• Moved to marketplace: 33,953
• ESI covers trials about 86% of the time
• 4,618 newly covered for CT participation
Commercial 1,154,985
(95% CI: 1,135,293 - 1,174,840)
• No change in CT coverage
Government 208,311
(95% CI: 194,803 - 221,656)
• Remained uninsured: 203,777
• Gained ESI: 35,609 (30,766 newly covered)
• Gained Medicaid: 5,732; (0 newly covered)
• Moved to marketplace: 19,013 (newly covered)
Uninsured 264,131
(95% CI: 247,532 - 279,267)
Kansans newly 
covered for 
clinical trial 
participation 
54,397
(95% CI: 44,149 - 64,244)
Fig. 3. Estimated Coverage for Clinical Trial Participation post-ACA.
Fig. 2. Estimated Coverage for Clinical Trial Participation pre-ACA.
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pation following the 2014 ACA provisions.
6. Discussion
Advancements in cancer treatment hinge critically on the ability
of researchers to conduct timely clinical trials. The United States
Food and Drug Administration requires all new treatments to un-
dergo rigorous testing through the clinical trial process before
granting approval for the treatment to be available on the market
[30]. Lack of adequate enrollment to clinical trials limits the
generalizability of results, can result in trial cancellation and in-
creases the timeline for regulatory approval of new therapies, thus
increasing ﬁnancial and health-related costs [4,9].
Most cancer clinical trials are designed to follow the currentguidelines of delivering cancer care with the investigational agent
being added to this treatment schema. The procedures and tests a
patient would receive for their disease are referred to as “routine or
standard of care” and are billed to the patient's insurance, provided
the deﬁnition of a qualiﬁed trial is met. The investigational pro-
cedures are paid for by the sponsor of the clinical trial, such as a
pharmaceutical company.
The ACA provision requiring coverage of routine care procedures
as part of a clinical trial seemed like a promising policy for elimi-
nating lack of insurance as a barrier to trial participation. However,
the effectiveness of the provision in expanding coverage is limited
by three key factors that differ across states: 1) the provision does
not apply to grandfathered self-insured plans, 2) the provision does
not address coverage limitations in Medicaid, 3) and the provision
does not address individuals who remain uninsured.
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coverage from1999 to 2011 showed an average decline of 11.75% for
adults aged 19-64 [31]. Using the state of Kansas for illustration,
this analysis shows an increase in insurance coverage for trial
participation for adults aged 19e64 from 69% to 72%. While over
ﬁfty thousand Kansans gained clinical trial coverage under the ACA
mandate and other provisions, nearly half a million individuals in
the state of Kansas remain at risk for not being able to access
treatment through a clinical trial. Although community organiza-
tions have historically had high enrollment rates [8], recent expe-
rience suggests that insurance is a limiting factor for as many as
four patients a week at one of the high enrolling National Cancer
Institute's Community Oncology Research Program sites (K.
Humphries, personal communication, January 5, 2015).
State-level policies interacting with ACA provisions would lead
to differences in coverage if the analysis were repeated for other
states. Prior to the 2014 mandate, although not documented in
previous literature [9,16,17], Kansas had a regulation in place
requiring insurance providers issuing policies in Kansas to cover
routine procedures as part of a cancer clinical trial.8 The regulation
does not apply to self-insured plans and these plans have been
granted grandfathered status for the purposes of ACA, meaning if
the planwas in existence prior to March 23, 2010 and no signiﬁcant
changes to the policy or cost have been made, these plans are not
subject to the mandates of the ACA. According to the Kansas In-
surance Commissioner's ofﬁce, approximately 40% of the plans sold
in Kansas are self-insured. Due to the process of how plans are ﬁled
with the State, it is not possible to determine how many of these
plans exclude clinical trial participation. To further delay access to
care through a clinical trial, the Kansas Insurance Department notes
it remains permissible for “companies selling health insurance in
the state to continue to renew policies that don't meet the re-
quirements of the ACA … for policy years beginning on or before
October 1, 2016” [32]. Over time, it is likely that companies will stop
issuing grandfathered plans as the cost of retaining the grand-
fathered status will be outweighed by the need to revise policies
due to the current economic climate. In the context of the analysis
presented above, elimination of grandfather status could lead to
signiﬁcant gains in cancer clinical trial coverage greater than the
current effects of the ACA implementation.
Kansas did not opt to expand Medicaid eligibility to 138% of the
federal poverty level (FPL) under the ACA, so adults without chil-
dren cannot qualify for Medicaid beneﬁts at any income level and
parents qualify for beneﬁts only with an income of 38% FPL or
below. Ultimately, this policy decision had little effect on the
number of individuals newly covered for clinical trials as Kansas
Medicaid does not cover trial participation. However, Medicaid
expansion would have reduced the number of individuals with no
health insurance coverage, providing for access to cancer screening
and prevention services.
The complexities of state-level policy differences have been
noted by others in the literature [9,16e18]. A pre-ACA announce-
ment issued by the HHS and the Department of Labor in the form of
“Frequently Asked Questions” stated there was not a plan to issue a
regulation on the implementation of the clinical trial coverage
mandate therefore leaving “the implementation details of this
provision up to the individual states, which is likely to produce a
patchwork of uneven and unpredictable coverage that will confuse
patients and their health care providers and impact timely access to
potentially life-extending research.” [23,33] This led to more than
50 organizations including patient advocacy and leading oncology
professional organizations to sign a letter dated June 18, 20138 K.A.R. 40-4-43.urging the Administration to issue regulations or guidance before
January 2014 for fear that, “implementation of this provisionwill be
very uneven across the country and many consumers may be de-
nied a new protection they should be guaranteed under the law”
[23]. This guidance was never issued. This study highlights some of
the areas where state policies continue to have uneven effects.
Limitations of this analysis include the cross-use of the data-
bases which include different samples. The ACS database is main-
tained by the US Census Bureau and the availability of geographic
data is limited [25]. Marketplace enrollment reported by HHS
included enrollments reported to CMS and does not include state
based exchanges. CMS reports a limitation of this data includes
having not captured insurance status prior to enrollment on
through the marketplace [26].
This study does not try to quantify the number of newly diag-
nosed cancer cases affected by the policy but rather attempts to
highlight challenges encountered once other identiﬁed barriers
that affect clinical trial participation are overcome.
7. Conclusions
Three main factors limit the effectiveness of the ACA provisions
in expanding clinical trial coverage: 1) ‘grandfathered’ self-funded
employer plans not subject to state Employee Retirement Income
Security Act (ERISA) regulations, 2) Medicaid coverage limits not
addressed under the ACA, 3) populations that remain uninsured.
Kansas saw a negligible increase in insurance coverage as a result of
the ACA and lack of insurance coverage is likely to remain a concern
for cancer clinical trial participants.
Author contributions
ChristineMackay and Tami Gurley-Calvez had full access to all of
the data in the study and take responsibility for the integrity of the
data and the accuracy of the data analysis.
Study concept and design: Mackay, Gurley-Calvez.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Mackay, Gurley-Calvez.
Critical revision of the manuscript for important intellectual con-
tent: All authors.
Statistical analysis: Mackay, Gurley-Calvez.
Administrative, technical, or material support: Gurley-Calvez.
Study supervision: Mackay.
Conﬂict of interest disclosures
All authors have completed and submitted the ICMJE Form for
Disclosure of Potential Conﬂicts of Interest and nonewere reported.
Acknowledgments
This study was not supported by outside funding.
References
[1] V.A. Hutchins, M.B. Samuels, A.M. Lively, Analyzing the affordable care act:
Essential health beneﬁts and implications for oncology, J. Oncol. Pract. 9
(2013) 73e77.
[2] American Cancer Society Cancer: Cancer Facts and Figures. http://www.
cancer.org/acs/groups/content/@research/documents/webcontent/acspc-
042151.pdf.
[3] P.N. Lara Jr., R. Higdon, N. Lim, et al., Prospective evaluation of cancer clinical
trial accrual patterns: Identifying potential barriers to enrollment, J. Clin.
Oncol. 19 (2001) 1728e1733.
[4] J.M. Unger, W.E. Barlow, D.P. Martin, et al., Comparison of survival outcomes
among ancer patients treated in and out of clinical trials, J. Natl. Cancer Inst.
106 (2014) 1e13.
[5] D.J. Weckstein, C.A. Thomas, I.F. Emery, et al., Assessment of perceived cost to
C.B. Mackay et al. / Contemporary Clinical Trials Communications 2 (2016) 69e7474the patient and other barriers to clinical trial participation, J. Oncol. Pract. 7
(2011) 330e333.
[6] R.L. Comis, J.D. Miller, C.R. Aldige, et al., Public attitudes toward participation
in cancer clinical trials, J. Clin. Oncol. 21 (2003) 830e835.
[7] E. Ward, M. Halpern, N. Schrag, et al., Association of insurance with cancer
care utilization and outcomes, CA Cancer J. Clin. 58 (2008) 9e31.
[8] D. St Germain, A.M. Denicoff, E.P. Dimond, et al., Use of the national cancer
institute community cancer centers program screening and accrual log to
address cancer clinical trial accrual, J. Oncol. Pract. 10 (2014) e73ee80.
[9] S.D. Ellis, W.R. Carpenter, L.M. Minasian, et al., Effect of state-mandated in-
surance coverage on accrual to community cancer clinical trials, Contemp.
Clin. Trials 33 (2012) 933e941.
[10] M.M. Byrne, S.L. Tannenbaum, S. Glück, et al., Participation in cancer clinical
trials: why are patients not participating? Med. Decis. Mak. 34 (2014)
116e126.
[11] D. Berlyn, Routine patient care in clinical trials: whose cost is it anyway?
J. Law Health 16 (2001) 77e102.
[12] D.P. Goldman, S.H. Berry, M.S. McCabe, et al., Incremental treatment costs in
national cancer institute-sponsored clinical trials, J. Am. Med. Assoc. 289
(2003) 2970e2977.
[13] C.L. Bennett, J.R. Adams, K.S. Knox, et al., Clinical trials: are they a good buy?
J. Clin. Oncol. 19 (2001) 4330e4339.
[14] T.N. Chirikos, J.C. Ruckdeschel, J.P. Krischer, Impact of clinical trials on the cost
of cancer care, Med. Care 39 (2001) 373e383.
[15] American Society of Clinical Oncology: State Laws and Cooperative Agree-
ments. http://www.asco.org/insurance-coverage-clinical-trial-participants.
[16] G. McBride, More states mandate coverage of clinical trial costs, but does it
make a difference? J. Natl. Cancer Inst. 95 (2003) 1268e1269.
[17] C.P. Gross, V. Murthy, Y. Li, et al., Cancer trial enrollment after state-mandated
reimbursement, J. Natl. Cancer Inst. 96 (2004) 1063e1069.
[18] P.L. Taylor, State payer mandates to cover care in US oncology trials: do sci-
ence and ethics matter? J. Natl. Cancer Inst. 102 (2010) 376e390.
[19] Kaiser Family Foundation: State Health Facts: Health Insurance Coverage of
Adults 19-64. http://kff.org/other/state-indicator/adults-19-64/.
[20] C. Phillips, NCI Cancer Bulletin Special Issue: Clinical Trials Enrollment: In-
surance Coverage Expanding for cancer Clinical Trials, National Cancer Insti-
tute, 2010.
[21] S.B. Edge, L.A. Zwelling, D.C. Hohn, The anticipated and unintendedconsequences of the patient protection and affordable care act on cancer
research, Cancer J. 16 (2010) 606e613.
[22] S.M. Kircher, A.B. Benson 3rd, M. Farber, et al., Effect of the accountable care
act of 2010 on clinical trial insurance coverage, J. Clin. Oncol. 30 (2012)
548e553.
[23] American Society of Clinical Oncology: ASCO Urges Administration to Provide
Clear ACA Guidance on Protecting Patient Access to Clinical Trials http://www.
asco.org/press-center/asco-urges-administration-provide-clear-aca-
guidance-protecting-patient-access-clinical.
[24] B.A. Biedrzycki, Decision making for cancer clinical trial participation: a sys-
tematic review, Oncol. Nurs. Forum 37 (2010) E387eE399.
[25] United States Census Bureau: American Community Survey: Public Use
Microdata Sample. https://www.census.gov/acs/www/data_documentation/
public_use_microdata_sample/.
[26] The Affordable Care Act Research Briefs: Health Insurance Marketplace:
Summary Enrollment Report, U.S. Department of Health & Human Services,
May 2014. ASPE Issue Brief, https://aspe.hhs.gov/sites/default/ﬁles/pdf/76876/
ib_2014Apr_enrollment.pdf.
[27] Center for Medicare and Medicaid Services: Medicare Clinical Trial Policies.
http://www.cms.gov/Medicare/Coverage/ClinicalTrialPolicies/.
[28] J.F. Klamerus, S.S. Bruinooge, X. Ye, et al., The impact of insurance on access to
cancer clinical trials at a comprehensive cancer center, Clin. Cancer Res. 16
(2010) 5997e6003.
[29] K.G. Carman, C. Eibner, Survey Estimates Net Gain of 9.3 Million American
Adults with Health Insurance. http://www.rand.org/blog/2014/04/survey-
estimates-net-gain-of-9-3-million-american-adults.html.
[30] United States Food and Drug Administration: How Drugs Are Developed and
Approved. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/
HowDrugsareDevelopedandApproved/default.htm.
[31] State Health Access Data Assistance Center, State level trends in employer
sponsored health insurance, 2013. SHADAC Report, http://www.rwjf.org/en/
library/research/2013/04/state-level-trends-in-employer-sponsored-health-
insurance.html.
[32] S. Praeger, Insurance Quarterly, The Kansas Insurance Department, State of
Kansas, Winter 2014.
[33] United States Department of Labor: FAQs about the Affordable Care Act
Implementation Part XV. http://www.dol.gov/ebsa/faqs/faq-aca15.html.
